Recent progress in fragment-based lead discovery

Current Opinion in Pharmacology

Volumn 9, Issue 5, 2009, Pages 615-621

  Schulz, Michèle N ^a   Hubbard, Roderick E ^a,b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Vernalis PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA KINASE INHIBITOR; HEAT SHOCK PROTEIN 90; JANUS KINASE INHIBITOR; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

BINDING KINETICS; COMPUTER MODEL; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENTHALPY; ENTROPY; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HIGH THROUGHPUT SCREENING; MOLECULAR LIBRARY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; DRUG DESIGN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; MOLECULAR STRUCTURE; PROTEOMICS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349425790     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.04.009     Document Type: Review

References (38)

1. Congreve M., Chessari G., Tisi D., and Woodhead A.J. Recent developments in fragment-based drug discovery. J Med Chem 51 (2008) 3661-3680. A comprehensive review of fragment-based practice and application, with particular emphasis on summarizing recent projects and successes.
2. Hubbard R.E., Chen I., and Davis B. Informatics and modeling challenges in fragment-based drug discovery. Curr Opin Drug Discov Dev 10 (2007) 289-297. A summary of the different approaches is taken to fragment screening, with a particular emphasis on reviewing the published strategies for the design of fragment libraries.
3. Hajduk P.J., and Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6 (2007) 211-219. Important retrospective of the impact of and developments in fragment methods in the 10 years since the first SAR by NMR publication.
4. Fischer M., and Hubbard R.E. Fragment-based ligand discovery. Mol Interv 9 (2009) 22-30
5. Alberts J.S., Blomberg N., Breeze A.L., Brown A.J.H., Burrows J.N., Edwards P.D., Folmer R.H.A., Geschwindner S., Griffen E.J., Kenny P.W., et al. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Curr Top Med Chem 7 (2007) 1600-1629
6. Lepre C. Fragment-based drug discovery using the SHAPES method. Expert Opin Drug Discov 2 (2007) 1555-1566
7. Hubbard R.E., Davis B., Chen I., and Drysdale M.J. The SeeDs approach: integrating fragments into drug discovery. Curr Top Med Chem 7 (2007) 1568-1581
8. Jhoti H., Cleasby A., Verdonk M., and Williams G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 11 (2007) 485-493
9. Pellecchia M., Bertini I., Cowburn D., Dalvit C., Giralt E., Jahnke W., James T.L., Homans S.W., Kessler H., Luchinat C., et al. Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov 7 (2008) 738-745. A comprehensive overview of how NMR methods contribute to drug discovery.
10. Siegal G., Ab E., and Schultz J. Integration of fragment screening and library design. Drug Discov Today 12 (2007) 1032-1039
11. Blomberg N., Cosgrove D.A., Kenny P.W., and Kolmodin K. Design of compound libraries for fragment screening. J Comput Aid Mol Des (2009) March 13 [Epub ahead of print]
12. Gianti E., and Sartori L. Identification and selection of "privileged fragments" suitable for primary screening. J Chem Inform Model 48 (2008) 2129-2139
13. Akritopoulou-Zanze I., and Hajduk P.J. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov Today 14 (2009) 291-297
14. L and Mcl-1. Bioorg Med Chem 16 (2008) 7443-7449
15. Hajduk P.J. SAR by NMR: putting the pieces together. Mol Interv 6 (2006) 266-272. A summary of the important elements of the original SAR by NMR approach from Abbott.
16. Hamalainen M.D., Zhukov A., Ivarsson M., Fex T., Gottfries J., Karlsson R., and Bjorsne M. Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels. J Biomol Screen 13 (2008) 202-209
17. Proll F., Fechner P., and Proll G. Direct optical detection in fragment-based screening. Anal Bioanal Chem 393 (2009) 1557-1562
18. Tummino PJ, Copeland RA: Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008, 47:5481-5492. The kinetics of binding (on and off rates) is becoming recognised as an important criteria for compound selection. It remains to be seen whether binding kinetics can be used to select which fragments to optimise.
19. Recht M.I., De Bruyker D., Bell A.G., Wolkin M.V., Peeters E., Anderson G.B., Kolatkar A.R., Bern M.W., Kuhn P., Bruce R.H., and Torres F.E. Enthalpy array analysis of enzymatic and binding reactions. Anal Biochem 377 (2008) 33-39
20. Freire E. Do enthalpy and entropy distinguish first in class from best in class?. Drug Discov Today 13 (2008) 869-874. Recent advances in calorimetry allow the direct measurement of the enthalpy and entropy contributions to binding energy. It remains to be seen whether these parameters can be used to select which fragments to optimise.
21. Hajduk P.J. Fragment-based drug design: how big is too big?. J Med Chem 49 (2006) 6972-6976. A landmark publication describing a retrospective analysis that tracks the ligand efficiency in fragment to lead optimisation campaigns. A number of important concepts are introduced which underpin much of the current thinking in fragment optimisation.
22. Hajduk P.J., and Sauer D.R. Statistical analysis of the effects of common chemical substituents on ligand potency. J Med Chem 51 (2008) 553-564
23. Verdonk M.L., and Rees D.C. Group efficiency: a guideline for hits-to-leads chemistry. Chem Med Chem 3 (2008) 1179-1180
24. Leeson P.D., and Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6 (2007) 881-890
25. Huth J.R., Park C., Petros A.M., Kunzer A.R., Wendt M.D., Wang X.L., Lynch C.L., Mack J.C., Swift K.M., Judge R.A., et al. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem Biol Drug Des 70 (2007) 1-12
26. Saxty G., Woodhead S.J., Berdini V., Davies T.G., Verdonk M.L., Wyatt P.G., Boyle R.G., Barford D., Downham R., Garrett M.D., and Carr R.A. Identification of inhibitors of protein kinase B using fragment-based lead discovery. J Med Chem 50 (2007) 2293-2296. This and the partner paper in the same volume describe alternate strategies (growing/merging) for the optimisation of fragments into lead candidates.
27. Thompson D.C., Denny R.A., Nilakantan R., Humblet C., Joseph-McCarthy D., and Feyfant E. CONFIRM: connecting fragments found in receptor molecules. J Comput Aid Mol Des 22 (2008) 761-772
28. Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield J.E., Cheung K.M.J., Collins I., Davies N.G.M., Drysdale M.J., et al. 4,5-Diarylisoxazole HSP90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51 (2008) 196-218
29. Crisman T.J., Bender A., Milik M., Jenkins J.L., Scheiber J., Sukuru S.C.K., Fejzo J., Hommel U., Davies J.W., and Glick M. "Virtual fragment linking": an approach to identify potent binders from low affinity fragment hits. J Med Chem 51 (2008) 2481-2491. One of the first published examples of how fragment screening may provide a 'window' into corporate compound collections, providing an alternative way that fragment-based discovery can sit alongside HTS within large corporations.
30. Howard S., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Curry J., Devine L.A., Early T.R., Fazal L., Gill A.L., et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 52 (2009) 379-388. The most recent publication from Astex providing a particularly elegant illustration of how structure-guided growth of a fragment leads rapidly to a potent inhibitor.
31. Antonysamy S.S., Hirst G., Park F., Sprengeler P., Stappenbeck F., Steensma R., Wilson M., and Wong M. Fragment-based discovery of JAK-2 inhibitors. Bioorg Med Chem Lett 19 (2009) 279-282
32. Hubbard R.E. Fragment approaches in structure-based drug discovery. J Synchrotron Radiat 15 (2008) 227-230
33. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
34. Congreve M., Aharony D., Albert J., Callaghan O., Campbell J., Carr R.A.E., Chessari G., Cowan S., Edwards P.D., Frederickson M., et al. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. J Med Chem 50 (2007) 1124-1132
35. Hohwy M., Spadola L., Lundquist B., Hawtin P., Dahmen J., Groth-Clausen I., Nilsson E., Persdotter S., Von Wachenfeldt K., Folmer R.H.A., and Edman K. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. J Med Chem 51 (2008) 2178-2186
36. Antonysamy S.S., Aubol B., Blaney J., Browner M.F., Giannetti A.M., Harris S.F., Hebert N., Hendle J., Hopkins S., Jefferson E., et al. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. Bioorg Med Chem Lett 18 (2008) 2990-2995
37. Chung F., Tisne C., Lecourt T., Dardel F., and Micouin L. NMR-guided fragment-based approach for the design of tRNA(Lys3) ligands. Angew Chem Intl Ed 46 (2007) 4489-4491
38. Wyatt P.G., Woodhead A.J., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Davis D.J., Devine L.A., Early T.R., Feltell R.E., et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 51 (2008) 4986-4999